Vanguard Group
ARIA

Vanguard Group’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Vanguard Group’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-14,591,103
Closed -$182M – 4108
2016
Q4 		$182M Buy
14,591,103
+1,462,029
+11% +$17.6M 0.01% 1238
2016
Q3 		$180M Buy
13,129,074
+404,675
+3% +$4.06M 0.01% 1193
2016
Q2 		$94M Buy
12,724,399
+259,003
+2% +$1.94M 0.01% 1555
2016
Q1 		$79.7M Buy
12,465,396
+319,610
+3% +$1.79M 0.01% 1623
2015
Q4 		$75.9M Buy
12,145,786
+265,133
+2% +$1.74M 0.01% 1658
2015
Q3 		$69.4M Buy
11,880,653
+342,715
+3% +$2.64M 0.01% 1690
2015
Q2 		$95.4M Buy
11,537,938
+364,370
+3% +$3.22M 0.01% 1557
2015
Q1 		$92.1M Buy
11,173,568
+437,583
+4% +$3.24M 0.01% 1557
2014
Q4 		$73.8M Buy
10,735,985
+300,266
+3% +$1.88M 0.01% 1620
2014
Q3 		$56.4M Sell
10,435,719
-220,220
-2% -$1.29M ﹤0.01% 1730
2014
Q2 		$67.9M Buy
10,655,939
+271,561
+3% +$1.87M 0.01% 1662
2014
Q1 		$83.7M Buy
10,384,378
+48,442
+0.5% +$377K 0.01% 1467
2013
Q4 		$70.5M Buy
10,335,936
+379,541
+4% +$2.05M 0.01% 1557
2013
Q3 		$183M Buy
9,956,395
+266,050
+3% +$5.17M 0.02% 889
2013
Q2 		$169M Buy
+9,690,345
New +$172M 0.02% 858

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.58% 1-Year Est. Return

Vanguard Group's ARIA Position: Q1 2017 in Review

Vanguard Group sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 14,591,103 shares — an estimated $182M sold.

Vanguard Group first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $183M in Q3 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Vanguard Group reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Vanguard Group sold 14,591,103 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $182M.
  • Vanguard Group first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
  • Vanguard Group's Ariad Pharmaceuticals Inc position peaked at $183M in Q3 2013.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Vanguard Group's 13F filing for Q1 2017, filed 12 May 2017.